Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration：A Single-Center, Prospective, Randomized Controlled Trial

NCT06994312 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT06994312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06994312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration：A Single-Center, Prospective, Randomized Controlled Trial
Lead sponsor
The First Hospital of Jilin University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 1, 2025
Completion date
December 1, 2028
Enrollment
282 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis-induced coagulopathy (sic)